J.C. Reubi

University of Bern — Switzerland

Medicine · Health Sciences

45h-index7.4kcitations88works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(40), Neuroblastoma Research and Treatments(16), Neuroscience and Neuropharmacology Research(15), Receptor Mechanisms and Signaling(13), Neuropeptides and Animal Physiology(11)

Publications86 total

New GRPR-antagonists mimicking [99mTc]Demobesin 1
Nuclear Medicine and Biology·2014
A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign
Recent results in cancer research/Recent Results in Cancer Research·2012· 1 cited
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
PubMed·2010· 7 cited
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
European Journal of Nuclear Medicine and Molecular Imaging·2010· 195 cited
Highly Potent 4-Amino-indolo[2,3-c]azepin-3-one-Containing Somatostatin Mimetics with a Range of sst Receptor Selectivities (vol 52, pg 95, 2009)
VUBIR (Vrije Universiteit Brussel)·2010
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Journal of Nuclear Medicine·2007· 457 citedOpen Access
Erratum to “Analgesic activity of a non-peptide imidazolidinedione somatostatin agonist: In vitro and in vivo studies in rat” [Pain 124 (2006) 34–49]
Pain·2006· 1 cited
Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists
Research and perspectives in endocrine interactions·2006· 1 cited
Comparative evaluation of 99mTc labeled Bombesin analogues for targeting GRP-RPositive neoplasms
World Journal of Nuclear Medicine·2004
[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging
European Journal of Nuclear Medicine and Molecular Imaging·2003· 195 citedOpen Access
Potent and Long-Acting Corticotropin Releasing Factor (CRF) Receptor 2 Selective Peptide Competitive Antagonists
Journal of Medicinal Chemistry·2002· 161 citedOpen Access
Localization and characterization of neuropeptide receptors in human colon
Naunyn-Schmiedeberg s Archives of Pharmacology·2001· 91 cited
Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets.
PubMed·2001· 188 cited
DOTAGA, a new chelator for Y-90 and In-111 based radiopeptides
Nuclear Medicine Communications·2000· 1 cited
The potential role of technetium labeled bombesin analogs in the detection of bombesin-positive tumors in vivo
Nuclear Medicine Communications·2000
Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
PubMed·1999· 81 cited
Regulatory peptide receptors in human hepatocellular carcinomas
Gut·1999· 111 citedOpen Access
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
PubMed·1999· 509 cited
Study of a Primary Gastrinoma in the Common Hepatic Duct – A Case Report
Digestion·1999· 25 cited
Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
PubMed·1996· 99 cited
page 1 of 5Next →

Frequent Co-authors

E. P. Krenning(11), Steven W. J. Lamberts(9), R. Maurer(7), Beatrice Waser(5), Willem H. Bakker(5), S.W.J. Lamberts(4), S. W. J. Lamberts(4), H.Y. Oei(4), Michel Cuénod(3), P. Martin van Hagen(3), Dik J. Kwekkeboom(3), D. J. Kwekkeboom(3), J.G.M. Klijn(2), Thomas M. Jessell(2), Wout A. P. Breeman(2), Marion de Jong(2), P.P.M. Kooij(2), Peter Marbach(2), Jeanetta du Plessis(2), Bob Löwenberg(2)